Integrated BioPharma, Inc. filings document formal disclosures for a Delaware operating company whose public reports are tied to vitamins, nutritional supplements, herbal products and contract manufacturing. Recent Form 8-K filings furnish quarterly and fiscal-year results under Item 2.02, including press-release exhibits covering revenue, operating results and per-share data.
The filing record also includes material-event reports on credit-line arrangements and related-party lease matters involving the wholly owned subsidiary Manhattan Drug Company, as well as definitive proxy materials and annual meeting voting results covering director elections, executive-compensation votes, stockholder voting matters and governance procedures. Cover-page disclosures identify no securities registered on a national exchange under Section 12(b).
Integrated BioPharma, Inc. (INBP) reported results for the quarter and fiscal year ended June 30, 2026. Quarterly revenue was $9.796 million, down 31.0% from $14.175 million a year earlier; the company recorded a $0.869 million operating loss and a $1.366 million net loss, versus operating income of $0.589 million and a net loss of $0.178 million.
Fiscal-year revenue differs between the results narrative and the statements of operations: the narrative reports $43.9 million, down 19.3% from $54.4 million, while the statements list $48.872 million for 2026 and $54.353 million for 2025. The statements also show a $2.705 million operating loss and $2.842 million net loss for 2026, versus $2.020 million operating income and $0.808 million net income in 2025. The two largest customers in the Contract Manufacturing Segment represented approximately 90% of total revenue in 2026, compared with 84% in 2025.
Integrated BioPharma, Inc. reported fiscal 2026 net sales of $43.872 million, down 19.3% from $54.353 million in fiscal 2025. Gross profit was $0.800 million, compared with $5.562 million. The company recorded an operating loss of $2.705 million versus operating income of $2.020 million, and a net loss of $2.842 million versus net income of $0.808 million.
Net cash provided by operating activities was $1.241 million, compared with $2.065 million; year-end cash rose to $4.471 million from $3.615 million. Two customers, Life Extension and Herbalife, accounted for approximately 90% of consolidated net sales in fiscal 2026, compared with 84% in fiscal 2025.
The committed revolving line of credit has a $4.000 million limit through April 14, 2027; a separate convertible line of credit note is capped at $250,000 for equipment and/or vehicle purchases. Management said operations, credit facilities and equipment financing are expected to support working capital requirements through the twelve-month period ending in September 2027. Agreements to develop, manufacture and supply products to Herbalife subsidiaries began January 1, 2026 and terminate December 31, 2028, without minimum purchase or supply commitments.
INTEGRATED BIOPHARMA, INC. (INBP) reported that its wholly owned subsidiary, Manhattan Drug Company, Inc. (MDC), has appointed Michael G. Richtmyer as Head of Operations. He joined MDC on August 3, 2026 and brings more than 35 years of senior operations and general management experience across pharmaceutical, nutraceutical, supplement, personal care, and contract manufacturing sectors.
Richtmyer will oversee operational strategy and execution at MDC, focusing on manufacturing performance, supply chain reliability, quality systems, productivity, and scalable growth. He previously served as President of Tishcon Corp., where he managed two vitamin, mineral, and supplement contract manufacturing sites and operations for more than 650 active products, and earlier worked with Integrated BioPharma from 1991 to 1999.
Integrated BioPharma, Inc. amended its loan agreement with PNC Bank, extending its existing committed revolving line of credit, which allows borrowings up to $4,000,000, to April 14, 2027. The company and its subsidiary also entered into a new $250,000 Convertible Line of Credit Note for equipment and vehicle purchases.
Before conversion, the new equipment line bears interest at a Daily Rate equal to one-month SOFR plus 250 basis points. The amendment also terminates a prior Convertible Equipment Line of Credit Note with a maximum amount of $500,000 that had matured and is no longer in effect.
INTEGRATED BIOPHARMA director Eric J. Friedman received a grant of stock options for 50,000 shares of common stock. The options have an exercise price of $0.19 per share and expire on June 24, 2036. They vest in four equal installments of 12,500 options on September 30, 2026, December 31, 2026, March 31, 2027, and June 30, 2027, giving him rights to purchase up to 50,000 shares once vested.
INTEGRATED BIOPHARMA INC director and 10% owner Damon DeSantis received a stock option grant covering 50,000 shares of common stock. The options carry an exercise price of $0.2000 per share and expire on June 24, 2036. Following this grant, DeSantis holds options for 50,000 shares directly. The award vests in four equal installments of 12,500 options on each of September 30, 2026, December 31, 2026, March 31, 2027, and June 30, 2027, meaning he can exercise portions of the grant over time as they vest.
INTEGRATED BIOPHARMA INC director Eric J. Friedman received a grant of stock options for 50,000 shares of Common Stock. These options have an exercise price of $0.1900 per share and expire on June 24, 2036. The grant is compensation-related rather than an open‑market purchase.
The options vest and become exercisable in four equal installments of 12,500 options each on September 30, 2026, December 31, 2026, March 31, 2027, and June 30, 2027, aligning vesting with future service periods.
INTEGRATED BIOPHARMA director Robert Canarick received a grant of 50,000 stock options for common stock. The options have an exercise price of $0.19 per share and expire on June 24, 2036. They vest in four equal installments of 12,500 options between September 2026 and June 2027.
Integrated BioPharma Inc. director William H. Milmoe received a grant of stock options to acquire 50,000 shares of Common Stock. The options have an exercise price of $0.19 per share and were awarded at no cost to him.
The options vest in four equal installments of 12,500 options each on September 30, 2026, December 31, 2026, March 31, 2027, and June 30, 2027, and expire on June 24, 2036. This is a routine compensation-related award rather than an open-market trade.
Integrated BioPharma, Inc. reported weaker results for the quarter ended March 31, 2026, with revenue of $10.1 million versus $13.9 million a year earlier, a 27.3% decline. The company swung from operating income of about $0.7 million to an operating loss of about $1.1 million, and from net income of about $0.6 million to a net loss of about $0.8 million, or $(0.03) per diluted share.
For the nine months ended March 31, 2026, revenue was $34.1 million compared to $40.2 million, down 15.2%, with a net loss of about $1.5 million versus net income of about $1.0 million a year earlier. Management noted that revenue from the two largest customers in the Contract Manufacturing Segment represented about 90% of total revenue in the 2026 period, up from 83% in 2025, underscoring significant customer concentration.